You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

AKT2

Showing 1 - 25 of 924
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Cancer, Prostate Cancer, Advanced Solid Tumors Trial in Middletown, Harrison, New York (AZD5363, Enzalutamide,

Active, not recruiting
  • Breast Cancer
  • +2 more
  • Middletown, New Jersey
  • +2 more
Jul 5, 2022

Locally Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Unresectable Malignant Solid Tumor Trial (Biopsy,

Not yet recruiting
  • Locally Advanced Malignant Solid Neoplasm
  • +2 more
  • Biopsy
  • +5 more
  • (no location specified)
Nov 8, 2022

Everolimus-containing Chemotherapy in HER2- mBC PI3K/AKT/mTOR

Completed
  • Breast Cancer
  • +2 more
  • No intervention, it was a retrospective study.
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Sep 13, 2021

Breast Tumor, Breast Cancer, Hormone Receptor Positive Tumor Trial in Shanghai (PIK3CA inhibitor, AKT inhibitor, Carrelizumab)

Recruiting
  • Breast Neoplasm
  • +4 more
  • PIK3CA inhibitor
  • +12 more
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Jan 2, 2023

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Canada (Laboratory Biomarker Analysis, Pharmacological

Completed
Has Results
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Laboratory Biomarker Analysis
  • +3 more
  • Calgary, Alberta, Canada
  • +4 more
Feb 10, 2022

Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma Trial in United States

Completed
Has Results
  • Endometrial Adenocarcinoma
  • +4 more
  • Akt Inhibitor MK2206
  • Laboratory Biomarker Analysis
  • Boston, Massachusetts
  • +6 more
Jan 13, 2022

Metastatic Breast Cancer Trial in Spain (Ipatasertib, Trastuzumab, Pertuzumab)

Recruiting
  • Metastatic Breast Cancer
  • Badalona, Barcelona, Spain
  • +9 more
Oct 24, 2022

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Metastatic

Not yet recruiting
  • FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
  • +4 more
  • Computed Tomography
  • +3 more
  • (no location specified)
Sep 13, 2022

Estrogen Receptor Positive Breast Cancer Trial in United Kingdom (AZD5363, Placebo, Fulvestrant)

Active, not recruiting
  • Estrogen Receptor Positive Breast Cancer
  • Manchester, Greater Manchester, United Kingdom
  • +20 more
Aug 5, 2022

Advanced Solid Malignancy, Safety and Tolerability, Pharmacokinetics Trial in Worldwide (AZD5363)

Active, not recruiting
  • Advanced Solid Malignancy
  • +13 more
  • Los Angeles, California
  • +33 more
Dec 22, 2022

Breast Cancer Trial in Beijing (Inetetamab, Rapamycin, Pyrotinib)

Not yet recruiting
  • Breast Cancer
  • Beijing, China
    National Cancer Center/National Clinical Research Center for Can
Jan 31, 2021

Langerhans Cell Histiocytosis Trial in United States (GSK2110183)

Completed
  • Langerhans Cell Histiocytosis
  • Baltimore, Maryland
  • +4 more
Sep 3, 2020

Gastric Cancer Trial in Worldwide (5-Fluorouracil, Ipatasertib, Leucovorin)

Completed
Has Results
  • Gastric Cancer
  • Los Angeles, California
  • +33 more
Feb 18, 2022

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma Trial in

Completed
Has Results
  • Adult Nasal Type Extranodal NK/T-cell Lymphoma
  • +35 more
  • Akt inhibitor MK2206
  • laboratory biomarker analysis
  • Houston, Texas
    M D Anderson Cancer Center
Oct 14, 2020

Advanced Cancer Trial in Newcastle, Sutton (olaparib, AZD5363)

Completed
  • Advanced Cancer
  • Newcastle, Newcastle Upon Tyne, United Kingdom
  • +1 more
Jan 31, 2020

Proteus Syndrome Trial run by the NHGRI (MK-7075 (miransertib))

Completed
  • Proteus Syndrome
  • MK-7075 (miransertib)
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Jun 29, 2022

Integrated Molecular Profiling in Advanced Cancers Trial

Active, not recruiting
  • Breast Cancer
  • +9 more
    • Toronto, Ontario, Canada
      Princess Margaret Hospital
    Sep 26, 2022

    Estrogen Receptor Negative, HER2/Neu Negative, Invasive Breast Carcinoma Trial in United States (Akt Inhibitor GSK2141795,

    Completed
    Has Results
    • Estrogen Receptor Negative
    • +6 more
    • Akt Inhibitor GSK2141795
    • +2 more
    • Washington, District of Columbia
    • +7 more
    Aug 27, 2019

    Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors Trial in Canada (Olaparib, Dasatinib, Nivolumab plus Ipilimumab)

    Recruiting
    • Lymphoma, Non-Hodgkin
    • +2 more
    • Edmonton, Alberta, Canada
    • +9 more
    Jan 9, 2023

    Breast Cancer, Hyperinsulinism, HER2-negative Breast Cancer Trial in New Haven (Dapagliflozin 10mg)

    Not yet recruiting
    • Breast Cancer
    • +2 more
    • Dapagliflozin 10mg
    • New Haven, Connecticut
      Yale Cancer Center Smilow Cancer Hospital
    Aug 3, 2023

    Metastatic Kidney Carcinoma, Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7 Trial in United States (Akt

    Terminated
    Has Results
    • Metastatic Kidney Carcinoma
    • +3 more
    • Akt Inhibitor MK2206
    • +2 more
    • Beverly Hills, California
    • +7 more
    Sep 25, 2019

    Advanced Malignant Solid Tumor, Stage III Cutaneous Melanoma AJCC v7, Stage III Prostate Cancer AJCC v7 Trial in New Brunswick

    Active, not recruiting
    • Advanced Malignant Solid Neoplasm
    • +9 more
    • New Brunswick, New Jersey
      Rutgers Cancer Institute of New Jersey
    Jan 25, 2023

    Prostate Cancer, Insulin Resistance, Diabetes, Type 2 Trial in Buffalo (Pioglitazone 30 mg, Placebo)

    Recruiting
    • Prostate Cancer
    • +3 more
    • Pioglitazone 30 mg
    • Placebo
    • Buffalo, New York
      Diabetes and Endocrinology Research Center of WNY
    Oct 26, 2022

    Premenopausal Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer Trial in Taipei City (Goserelin, Fulvestrant,

    Recruiting
    • Premenopausal Breast Cancer
    • +2 more
    • Taipei City, Taiwan
      Department of Oncology, National Taiwan University Hospital
    Feb 7, 2023

    Bile Acids in Acute Insulin Resistance

    Recruiting
    • PI3K Gene Mutation
    • +4 more
    • Drug-induced acute insulin resistance due to PI3K inhibitor, AKT inhibitor, or mTOR inhibitor
    • New York, New York
      Columbia University Medical Center
    Oct 6, 2022